There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .
Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women.
CONTEXT Recent studies disputed the widely promoted anti-aging effect of dehydroepi and rosterone ( DHEA ) supplementation ; however , conflicting data exist on whether physiological DHEA supplementation enhances exercise training effects on body composition , physical performance , and cardiometabolic risk in healthy postmenopausal women . OBJECTIVE The aim of this study was to determine whether 12 wk of DHEA supplementation ( 50 mg/d ) in postmenopausal women enhances exercise-related changes in body composition , physical performance , and cardiometabolic risk . DESIGN AND SETTING This study was a 12-wk r and omized double-blind , placebo-controlled trial and took place at the Mayo Clinic General Clinical Research Center ( Rochester , MN ) . PARTICIPANTS Thirty-one sedentary , postmenopausal , Caucasian women ( mean + /- sem age 64.6 + /- 1.0 yr ) completed the study . INTERVENTION Participants were r and omized to one of two 12-wk interventions : 1 ) exercise training plus 50 mg/d of DHEA ( n = 17 ) , or 2 ) exercise training plus placebo ( n = 14 ) . The exercise intervention consisted of both endurance ( 4 d/wk ) and resistance ( 3 d/wk ) exercise components . MAIN OUTCOME MEASURES The main outcomes were measures of body composition , physical performance , and measures of cardiometabolic risk . RESULTS DHEA treatment with exercise result ed in increases in circulating sulfated DHEA ( 650 % ) , total testosterone ( 100 % ) , estradiol ( 165 % ) , estrone ( 85 % ) , and IGF-I ( 30 % ) ( all P < or = 0.05 , for all within and between treatment comparisons ) . Although exercise training alone significantly improved physical performance , body composition , and insulin sensitivity , administration of DHEA provided no additional benefits . CONCLUSIONS Twelve weeks of combined endurance and resistance training significantly improved body composition , physical performance , insulin sensitivity , and low-density lipoprotein cholesterol particle number and size , whereas DHEA had no additional benefits
There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .